AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

โ† Trials
๐Ÿงช

Effects of PERMISSive Lung-protective Ventilation on Outcome in Critically Ill Invasively Ventilated Patients

RecruitingNAAges 18 Years - anyAllReinier de Graaf Groep
๐Ÿ’ฌ

In plain words

What the trial is, and whether it could suit you

RATIONALE Lung-protective ventilation using a lower respiratory rate (RR) is an appealing strategy to reduce ventilation intensity, which may require permissive hypercapnia. However, the feasibility and safety of this so-called 'permissive lung-protective ventilation' must be investigated, before conducting a large randomized clinical trial to evaluate its effectiveness on patient-centered outcomes. OBJECTIVE To study the feasibility and safety of permissive lung-protective ventilation in adult critically ill patients receiving invasive ventilation for acute hypoxemic respiratory failure, and to inform the design of a future randomized clinical trial in this patient population. HYPOTHESIS Permissive lung-protective ventilation is a feasible and safe ventilation strategy. STUDY DESIGN Multicenter, randomized clinical pilot trial. STUDY POPULATION Critically ill patients, aged \> 18 yea

Sign in to get the eligibility rules as simple questions to take to your doctor.

๐Ÿ“‹ Eligibility rules (as published)
Inclusion Criteria: * admission to one of the participating ICUs; * intubated and receiving invasive ventilation with an expected duration of ventilation of at least 24 hours. Exclusion Criteria: * age below 18 years; * receiving invasive ventilation \> 1 hour in the ICU, or receiving invasive ventilation \> 6 hours directly preceding the current ICU admission (i.e., in the operating room or in the emergency department); * receiving or planned to receive veno-venous, veno-arterial or arterio-venous extracorporeal membrane oxygenation (ECMO); * having COPD GOLD III and IV; * contra-indication for hypercapnia, such as ongoing cardiac ischemia (as defined in the guideline of the European Society of Cardiology), or having suspected or confirmed increased intracranial pressure due to brain injury, judged by the attending physician; * any neurologic diagnosis that can prolong duration of mechanical ventilation, e.g., Guillain-Barrรฉ syndrome, high spinal cord lesion or amyotrophic lateral sclerosis, multiple sclerosis, or myasthenia gravis; * suspected or confirmed pregnancy; * participation in another interventional trial using similar endpoints; * previously randomized in this study; * no informed consent; or * admitted for terminal care
๐Ÿ’Š

What it tests

  • Permissive lung-protective ventilation
  • Conventional lung-protective ventilation
๐Ÿ“

Where

5 sites
ZiekenhuisGroep Twente
Almelo, Netherlands
Amsterdam UMC
Amsterdam, Netherlands
Reinier de Graaf Hospital
Delft, Netherlands
Dijklander Hospital
Hoorn, Netherlands
Vall d'Hebron
Barcelona, Spain
๐Ÿค Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible โ€” always decide together with your own doctor.
๐Ÿ›ก๏ธ

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it โ€” not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use ยท Privacy